BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) finished Wednesday with an addition of $0.28 to close at $14.99, an upside of 1.90 percent. An average of 2,145,620 shares of common stock have been traded in the last five days. There was a gain of $1.46 in the past week. The last 20 days have seen an average of 2,456,970 shares traded, while the 50-day average volume stands at 2,785,288.
BCRX stock has decreased by -3.17% in the last month. The company shares reached their 1-month lowest point of $13.10 on 10/04/21. With the stock rallying to its 52-week high on 08/06/21, shares of the company touched a low of $3.46 and a high of $18.48 in 52 weeks. In spite of this, the price is down -18.89% from the 52-week high.
A Backdoor Way To Profit From Today’s Crypto Bull Market
In any crypto bull market, there's a lot of money to be made.
But what if we told you the best opportunities are not cryptocurrencies themselves… but instead, simply crypto stocks?
This strategy is simply and ridiculously easy.
Here are 6 ways to gain exposure to crypto outside the norm. This is arguably the safest bet you can make.
29 days have passed since BioCryst Pharmaceuticals Inc. (BCRX) last reported insider trading activity. ABERCROMBIE GEORGE B, who is Director, most recently acquired $5,000 shares at $15.06 per share on Sep 15. In this transaction, the insider spent $75,300. Director, LEE KENNETH B JR, disposed of 6,000 shares at a price of $15.35 on Sep 13. The insider now owns more than $92,100 worth of shares. Prior to that, Director ABERCROMBIE GEORGE B went on to Sale 74,000 shares at $15.09 each on Sep 10. An amount of $1,116,660 was transacted.
BioCryst Pharmaceuticals Inc. (BCRX) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.30 for the sector. The stock’s beta is 2.56. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 32.72.
The quick ratio of BioCryst Pharmaceuticals Inc. for the three months ended June 29 was 2.20, and the current ratio was 2.30, indicating that the company is able to meet its debt obligations. On the profitability front, the trailing 12-month gross margin is 90.10% against a 5-year average of 92.6%. BioCryst Pharmaceuticals Inc.’s EBITDA margin for the year ending June 29 is -948.70%. Its gross profit as reported stood at $16.26 million compared to revenue of $17.81 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, BioCryst Pharmaceuticals Inc.’s return on assets was -79.80%, compared to -60.5% over the last five years. In the past year, the return on investment has been -69.30%, and the 5-year average is -77.5%. Meanwhile, the return on equity (ROE) for the past 12 months has been 513.80% and the 5-year average holds at -540.9%.
For the three-month period that ended June 29, BioCryst Pharmaceuticals Inc. had $8.11 million in cash. The analyst consensus anticipated BioCryst Pharmaceuticals Inc.’s latest quarter earnings to come in at -$0.24 per share, but it turned out to be -$0.24, a 0.00% surprise. For the quarter, EBITDA amounted to -$29.7 million. Shareholders own equity worth $178.87 million.
From a technical analysis perspective, let’s take a brief look at BioCryst Pharmaceuticals Inc. (BCRX) price momentum. RSI 9-day as of the close on 13 October was 58.80%, suggesting the stock is Neutral, with historical volatility in this time frame at 44.11%.
As of today, BCRX’s price is $14.51 +10.79% or $1.46 from its 5-day moving average. BCRX is currently trading -0.53% lower than its 20-day SMA and +8.15% higher than its 100-day SMA. However, the stock’s current price level is -10.56% below the SMA50 and +108.77% above the SMA200.
The stochastic %K and %D were 66.60% and 56.57%, respectively, and the average true range (ATR) was 0.54. With the 14-day stochastic at 80.43% and the average true range at 0.57, the RSI (14) stands at 53.06%. The stock has reached 0.61 on the 9-day MACD Oscillator while the 14-day reading was at 0.38.
Jefferies downgraded BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) to a a Hold rating in its most recent analyst report. Previously, the stock was rated as a a Buy.The consensus rating for BioCryst Pharmaceuticals Inc. (BCRX) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell BCRX, while 3 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 8 others rate it as a “buy”.
What is BCRX’s price target for the next 12 months?
Analysts predict a range of price targets between $16.00 and $30.00, with a median target of $21.00. Taking a look at these predictions, the average price target given by analysts for BioCryst Pharmaceuticals Inc. (BCRX) stock is $21.27.